Lumira, Caisse de dépôt Join $42.5M Funding of Argos Therapeutics
Durham, North Carolina-based Argos Therapeutics Inc., a biopharmaceutical company focused on immunotherapies for the treatment of cancer and infectious diseases, has secured US$42.5 million in a Series E financing round. The deal was led by strategic investor Pharmstandard International S.A. (Luxembourg), with the participation of Green Cross Corp. and existing investors. Among the latter were Canadian venture capital firm Lumira Capital, pension fund manager the Caisse de dépôt et placement du Québec and TVM Capital, which manages the Montréal-based TVM Capital Life Science Venture Capital.
30 August 2013•4 mins read
